Is	O
there	O
a	O
role	O
for	O
surgical	B:C0728940
resection	I:C0728940
in	O
patients	O
with	O
pancreatic	O
cancer	I:C0030297
with	O
liver	O
metastases	I:C0494165
responding	O
to	O
chemotherapy	O
?	O

Is	O
there	O
a	O
role	O
for	O
surgical	O
resection	I:C0728940
in	O
patients	O
with	O
pancreatic	B:C0030297
cancer	I:C0030297
with	O
liver	O
metastases	I:C0494165
responding	O
to	O
chemotherapy	O
?	O

Is	O
there	O
a	O
role	O
for	O
surgical	O
resection	I:C0728940
in	O
patients	O
with	O
pancreatic	O
cancer	I:C0030297
with	O
liver	B:C0494165
metastases	I:C0494165
responding	O
to	O
chemotherapy	O
?	O

Is	O
there	O
a	O
role	O
for	O
surgical	O
resection	I:C0728940
in	O
patients	O
with	O
pancreatic	O
cancer	I:C0030297
with	O
liver	O
metastases	I:C0494165
responding	O
to	O
chemotherapy	B:C3665472
?	O

New	O
chemotherapeutic	B:C0392920
regimens	I:C0392920
have	O
improved	O
survival	O
for	O
stage	O
IV	I:C0441772
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
and	O
occasionally	O
major	O
response	O
of	O
liver	O
metastases	I:C0494165
can	O
be	O
observed	O
.	O

New	O
chemotherapeutic	O
regimens	I:C0392920
have	O
improved	O
survival	O
for	O
stage	B:C0441772
IV	I:C0441772
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
and	O
occasionally	O
major	O
response	O
of	O
liver	O
metastases	I:C0494165
can	O
be	O
observed	O
.	O

New	O
chemotherapeutic	O
regimens	I:C0392920
have	O
improved	O
survival	O
for	O
stage	O
IV	I:C0441772
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
and	O
occasionally	O
major	O
response	O
of	O
liver	O
metastases	I:C0494165
can	O
be	O
observed	O
.	O

New	O
chemotherapeutic	O
regimens	I:C0392920
have	O
improved	O
survival	O
for	O
stage	O
IV	I:C0441772
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
and	O
occasionally	O
major	O
response	B:C1704632
of	O
liver	O
metastases	I:C0494165
can	O
be	O
observed	O
.	O

New	O
chemotherapeutic	O
regimens	I:C0392920
have	O
improved	O
survival	O
for	O
stage	O
IV	I:C0441772
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
and	O
occasionally	O
major	O
response	O
of	O
liver	B:C0494165
metastases	I:C0494165
can	O
be	O
observed	O
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	B:C3665472
for	O
liver	O
metastases	I:C0494165
from	O
pancreatic	O
cancer	I:C0030297
and	O
to	O
evaluate	O
the	O
results	O
of	O
surgical	O
resection	I:C0728940
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	B:C0494165
metastases	I:C0494165
from	O
pancreatic	O
cancer	I:C0030297
and	O
to	O
evaluate	O
the	O
results	O
of	O
surgical	O
resection	I:C0728940
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	O
metastases	I:C0494165
from	O
pancreatic	B:C0030297
cancer	I:C0030297
and	O
to	O
evaluate	O
the	O
results	O
of	O
surgical	O
resection	I:C0728940
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	O
metastases	I:C0494165
from	O
pancreatic	O
cancer	I:C0030297
and	O
to	O
evaluate	B:C0220825
the	O
results	O
of	O
surgical	O
resection	I:C0728940
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	O
metastases	I:C0494165
from	O
pancreatic	O
cancer	I:C0030297
and	O
to	O
evaluate	O
the	O
results	B:C0456984
of	O
surgical	O
resection	I:C0728940
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	O
metastases	I:C0494165
from	O
pancreatic	O
cancer	I:C0030297
and	O
to	O
evaluate	O
the	O
results	O
of	O
surgical	B:C0728940
resection	I:C0728940
.	O

Retrospective	B:C0035363
analysis	I:C0035363
.	O

patients	O
with	O
extra-hepatic	B:C0205054
metastases	O
,	O
patients	O
with	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
performance	I:C1520224
status	I:C1520224
≥3	O
,	O
patients	O
undergoing	O
supportive	O
care	I:C0344211
alone	O
.	O

patients	O
with	O
extra-hepatic	O
metastases	B:C0027627
,	O
patients	O
with	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
performance	I:C1520224
status	I:C1520224
≥3	O
,	O
patients	O
undergoing	O
supportive	O
care	I:C0344211
alone	O
.	O

patients	O
with	O
extra-hepatic	O
metastases	O
,	O
patients	O
with	O
Eastern	B:C1520224
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
performance	I:C1520224
status	I:C1520224
≥3	O
,	O
patients	O
undergoing	O
supportive	O
care	I:C0344211
alone	O
.	O

patients	O
with	O
extra-hepatic	O
metastases	O
,	O
patients	O
with	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
performance	I:C1520224
status	I:C1520224
≥3	O
,	O
patients	O
undergoing	O
supportive	B:C0344211
care	I:C0344211
alone	O
.	O

Liver	B:C0494165
metastases	I:C0494165
were	O
unilobar	O
in	O
28.5	O
%	O
of	O
patients	O
.	O

Chemotherapy	B:C0392920
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	B:C0045093
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	B:C0450442
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	B:C0069717
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	B:C0123931
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	B:C0016360
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	B:C0023413
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	B:C0879464
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	B:C0008838
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	B:C0045093
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	B:C0671970
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	B:C0014582
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	B:C0392920
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	B:C0671970
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	B:C0246415
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	B:C0392920
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	B:C0014582
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	B:C0016360
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

Chemotherapy	O
regimens	I:C0392920
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	B:C0392920
)	O
(	O
48	O
%	O
)	O
.	O

56	O
patients	O
(	O
44	O
%	O
)	O
had	O
a	O
complete	O
(	O
7	O
%	O
)	O
or	O
partial	O
response	B:C1704632
(	O
37	O
%	O
)	O
.	O

surgical	B:C0728940
resection	I:C0728940
was	O
carried	O
out	O
in	O
11	O
patients	O
(	O
8.5	O
%	O
)	O
.	O

Median	O
overall	O
survival	O
was	O
11	O
months	O
for	O
the	O
entire	O
cohort	B:C0599755
and	O
15	O
months	O
for	O
those	O
with	O
partial	O
/	O
complete	O
response	O
.	O

Median	O
overall	O
survival	O
was	O
11	O
months	O
for	O
the	O
entire	O
cohort	O
and	O
15	O
months	O
for	O
those	O
with	O
partial	O
/	O
complete	O
response	B:C1704632
.	O

In	O
this	O
sub	B:C1515021
-	I:C1515021
group	I:C1515021
median	O
survival	O
was	O
significantly	O
longer	O
(	O
46	O
versus	O
11	O
months	O
)	O
for	O
patients	O
undergoing	O
resection	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
this	O
sub	O
-	I:C1515021
group	I:C1515021
median	O
survival	O
was	O
significantly	O
longer	O
(	O
46	O
versus	O
11	O
months	O
)	O
for	O
patients	O
undergoing	O
resection	B:C0728940
(	O
P	O
<	O
0.0001	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	B:C3665472
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	I:C0494165
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	O
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	B:C0450442
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	I:C0494165
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	O
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	B:C0728940
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	I:C0494165
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	O
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	B:C0494165
metastases	I:C0494165
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	O
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	I:C0494165
at	O
diagnosis	B:C0011900
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	O
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	I:C0728940
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	I:C0494165
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	B:C0201551
19.9	I:C0201551
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Surgical	B:C0728940
resection	I:C0728940
of	O
primary	O
pancreatic	O
tumor	I:C0030297
with	O
or	O
without	O
residual	O
liver	O
disease	I:C0023895
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	O
and	O
it	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Surgical	O
resection	I:C0728940
of	O
primary	O
pancreatic	B:C0030297
tumor	I:C0030297
with	O
or	O
without	O
residual	O
liver	O
disease	I:C0023895
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	O
and	O
it	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Surgical	O
resection	I:C0728940
of	O
primary	O
pancreatic	O
tumor	I:C0030297
with	O
or	O
without	O
residual	O
liver	B:C0023895
disease	I:C0023895
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	O
and	O
it	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Surgical	O
resection	I:C0728940
of	O
primary	O
pancreatic	O
tumor	I:C0030297
with	O
or	O
without	O
residual	O
liver	O
disease	I:C0023895
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	B:C3665472
and	O
it	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Surgical	O
resection	I:C0728940
of	O
primary	O
pancreatic	O
tumor	I:C0030297
with	O
or	O
without	O
residual	O
liver	O
disease	I:C0023895
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	O
and	O
it	O
is	O
associated	O
with	O
improved	B:C0184511
survival	O
.	O

